{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:47:04Z","timestamp":1783529224464,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.autrev.2022.103158","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T22:39:34Z","timestamp":1658961574000},"page":"103158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Vinicius","family":"Domingues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Yupei","family":"Chock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Dufrost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Risse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya V.","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Barbhaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Sartelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Zuily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.autrev.2022.103158_bb0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.1992.03490110089036","article-title":"Antiphospholipid antibody syndrome","volume":"268","author":"Lockshin","year":"1992","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.autrev.2022.103158_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost JTH"},{"issue":"2","key":"10.1016\/j.autrev.2022.103158_bb0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005792-197103000-00001","article-title":"The natural history of systemic lupus erythematosus by prospective analysis","volume":"50","author":"Estes","year":"1971","journal-title":"Medicine (Baltimore)"},{"issue":"275","key":"10.1016\/j.autrev.2022.103158_bb0020","first-page":"319","article-title":"SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up","volume":"74","author":"Worrall","year":"1990","journal-title":"Q J Med"},{"issue":"8","key":"10.1016\/j.autrev.2022.103158_bb0025","first-page":"1181","article-title":"Renal involvement in primary antiphospholipid syndrome","volume":"19","author":"Amigo","year":"1992","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103158_bb0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.53.1.67","article-title":"Deterioration of renal function in a patient with lupus","volume":"53","author":"Rankin","year":"1994","journal-title":"Ann Rheum Dis"},{"issue":"9751","key":"10.1016\/j.autrev.2022.103158_bb0040","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000188671","article-title":"The role of antiphospholipid antibodies in lupus nephropathy","volume":"71","author":"Perdiguero","year":"1995","journal-title":"Nephron."},{"issue":"3","key":"10.1016\/j.autrev.2022.103158_bb0050","first-page":"335","article-title":"Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies","volume":"20","author":"Sipek-Dolnicar","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103158_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000421701","article-title":"Clinical implication of antiphospholipid antibodies in systemic lupus erythematosus","volume":"99","author":"Stratta","year":"1992","journal-title":"Contrib Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0060","first-page":"332","article-title":"Histological features of antiphospholipid nephropathy in patients with Systemic Lupus Erythematosus","volume":"25","author":"Naseeb","year":"2015","journal-title":"J Coll Physicians Surg--Pak JCPSP"},{"issue":"14","key":"10.1016\/j.autrev.2022.103158_bb0065","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1177\/0961203318809177","article-title":"Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies","volume":"27","author":"Shah","year":"2018","journal-title":"Lupus."},{"issue":"8","key":"10.1016\/j.autrev.2022.103158_bb0070","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.1985.00360080059007","article-title":"Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants","volume":"145","author":"Glueck","year":"1985","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0272-6386(12)70258-5","article-title":"Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study","volume":"20","author":"Farrugia","year":"1992","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"2","key":"10.1016\/j.autrev.2022.103158_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejr.2012.01.001","article-title":"Comparative study of kidney affection in SLE patients with and without antiphospholipid syndrome","volume":"34","author":"Gaber","year":"2012","journal-title":"Egypt Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103158_bb0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00296-013-2900-3","article-title":"Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study","volume":"34","author":"Erre","year":"2014","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.autrev.2022.103158_bb0090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/rheumatology\/40.8.863","article-title":"Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone","volume":"40","author":"Moss","year":"2001","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"10.1016\/j.autrev.2022.103158_bb0095","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0961203310397410","article-title":"Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"20","author":"Silvari\u00f1o","year":"2011","journal-title":"Lupus."},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000013615","article-title":"Anticardiolipin antibodies in south African patients with lupus nephritis: a clinical and renal pathological study","volume":"20","author":"Naiker","year":"2000","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103158_bb0105","first-page":"503","article-title":"Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome","volume":"33","author":"Hernandez-Molina","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0110","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/096120339400300106","article-title":"Renal biopsy in systemic lupus erythematosus: significance of glomerular thrombosis. Analysis of 108 cases","volume":"3","author":"Miranda","year":"1994","journal-title":"Lupus."},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.reuma.2008.12.011","article-title":"Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE)","volume":"5","author":"Miranda","year":"2009","journal-title":"Reumatol Clin"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/096120339600500113","article-title":"The significance of anticardiolipin antibodies in patients with lupus nephritis","volume":"5","author":"Abu-Shakra","year":"1996","journal-title":"Lupus."},{"issue":"2","key":"10.1016\/j.autrev.2022.103158_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00005792-198103000-00001","article-title":"Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance","volume":"60","author":"Kant","year":"1981","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.autrev.2022.103158_bb0135","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ki.1991.155","article-title":"Significance of anti-phospholipid antibodies in patients with lupus nephritis","volume":"39","author":"Frampton","year":"1991","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0140","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/acr.22200","article-title":"Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients","volume":"66","author":"Jordan","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.autrev.2022.103158_bb0145","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3856","article-title":"Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis","volume":"14","author":"Gonzalo","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2022.103158_bb0150","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3899\/jrheum.151395","article-title":"Beta2-glycoprotein I expression in lupus nephritis patients with Antiphospholipid-associated nephropathy","volume":"43","author":"Gao","year":"2016","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103158_bb0155","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/art.23662","article-title":"Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0165","first-page":"235","article-title":"Renal thrombotic Microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: a case-control study","volume":"22","author":"Barrera-Vargas","year":"2016","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"8","key":"10.1016\/j.autrev.2022.103158_bb0170","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0175","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1440-1797.2007.00792.x","article-title":"Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies","volume":"12","author":"Cheunsuchon","year":"2007","journal-title":"Nephrol Carlton Vic"},{"issue":"10","key":"10.1016\/j.autrev.2022.103158_bb0180","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases","volume":"19","author":"Shen","year":"2010","journal-title":"Lupus."},{"issue":"8","key":"10.1016\/j.autrev.2022.103158_bb0185","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/rheumatology\/kep152","article-title":"Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies","volume":"48","author":"Galindo","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2022.103158_bb0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-015-0614-5","article-title":"Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up","volume":"17","author":"Gerhardsson","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2022.103158_bb0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J Am Soc Nephrol JASN"},{"issue":"6","key":"10.1016\/j.autrev.2022.103158_bb0200","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/91.6.401","article-title":"Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis","volume":"91","author":"Bhandari","year":"1998","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"5","key":"10.1016\/j.autrev.2022.103158_bb0205","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.02870311","article-title":"Evaluation of clinical outcomes and renal vascular pathology among patients with lupus","volume":"7","author":"Barber","year":"2012","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"10","key":"10.1016\/j.autrev.2022.103158_bb0210","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0961203317692419","article-title":"Prognostic significance of renal vascular pathology in lupus nephritis","volume":"26","author":"Mej\u00eda-Vilet","year":"2017","journal-title":"Lupus."},{"issue":"4","key":"10.1016\/j.autrev.2022.103158_bb0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int"},{"issue":"Suppl","key":"10.1016\/j.autrev.2022.103158_bb0220","article-title":"Increased Risk of Thrombocytopenia Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis","author":"Chock","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2022.103158_bb0225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.111.028522","article-title":"Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies","volume":"124","author":"Zuily","year":"2011","journal-title":"Circulation."},{"issue":"6","key":"10.1016\/j.autrev.2022.103158_bb0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2017.04.003","article-title":"Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: a systematic review and meta-analysis","volume":"16","author":"Zuily","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2022.103158_bb0235","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103158_bb0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11926-017-0687-z","article-title":"Vascular manifestations in Antiphospholipid syndrome (APS): is APS a thrombophilia or a vasculopathy?","volume":"19","author":"Siddique","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"S10","key":"10.1016\/j.autrev.2022.103158_bb0245","article-title":"Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis\/racemosa","volume":"70","author":"Sevim","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2022.103158_bb0250","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th international congress on Antiphospholipid antibodies task force report on Antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus."},{"issue":"9","key":"10.1016\/j.autrev.2022.103158_bb0255","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-020-00935-2","article-title":"Management of non-criteria Manifestations in Antiphospholipid syndrome","volume":"22","author":"Xourgia","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2022.103158_bb0260","series-title":"Identifying and measuring heterogeneity","year":"2011"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:24:44Z","timestamp":1761600284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1568997222001288"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103158","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103158"}}